TB-500 vs BNP (B-type Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Side-by-Side Comparison
| Aspect | TB-500 | BNP (B-type Natriuretic Peptide) |
|---|---|---|
| Mechanism | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. |
| Typical Dosage | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. |
| Administration | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. |
| Side Effects | May cause temporary fatigue, headache, or localized irritation at injection sites. | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. |
| Best For |
What They Have in Common
Both TB-500 and BNP (B-type Natriuretic Peptide) are commonly used for: